SCHEMBL4070603

SCHEMBL4070603

CCC(=O)Cc1cccc2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.65
ATM Q13315 1/20 0.54
L3MBTL1 Q9Y468 3/20 0.53
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.50
SIRT5 Q9NXA8 1/20 0.50
LMNA P02545 2/20 0.49
PKM P14618 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
ACP3 P15309 1/20 0.49
VNN1 O95497 1/20 0.48
KDM4E B2RXH2 2/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C19 P33261 1/20 0.48
MAPK8 P45983 1/20 0.48
MAPK9 P45984 1/20 0.48
MAPK10 P53779 1/20 0.48
HPGD P15428 1/20 0.48
PTGER4 P35408 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29875700 1.00 TDP1 (0.65) TDP1ATML3MBTL1KMT2AMEN1
SCHEMBL28879925 0.90 TDP1 (0.53) TDP1ATML3MBTL1KMT2AMEN1
SCHEMBL7565966 0.88 TDP1 (0.74) TDP1ATML3MBTL1KMT2AMEN1
SCHEMBL30774302 0.88 TDP1 (0.74) TDP1ATML3MBTL1KMT2AMEN1
SCHEMBL7196924 0.87 TDP1 (0.62) TDP1ATML3MBTL1KMT2AMEN1
SCHEMBL29875565 0.87 TDP1 (0.62) TDP1ATML3MBTL1KMT2AMEN1
SCHEMBL28879878 0.84 TDP1 (0.46) TDP1ATML3MBTL1KMT2AMEN1
Propionic Acid SCHEMBL28091563 0.84 TDP1 (0.86) TDP1ATML3MBTL1KMT2AMEN1
SCHEMBL31204231 0.83 TDP1 (0.67) TDP1ATML3MBTL1KMT2AMEN1
SCHEMBL8400463 0.82 IAPP (0.58) TDP1ACP3KDM4ECYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240024497-A1 METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES CIDARA THERAPEUTICS, INC. 2024-01-25 US disclosed
US-11833213-B2 Compositions and methods for the treatment of viral infections CIDARA THERAPEUTICS, INC. (US) 2023-12-05 US disclosed
EP-4139275-A1 COMPOUNDS AND PHARMACEUTICAL USES THEREOF Syneurx International (Taiwan) Corp. (TW) 2023-03-01 EP disclosed
CN-114956933-A Marker containing isotope oxygen atom and preparation method and application thereof 清华大学 2022-08-30 CN disclosed
WO-2021213500-A1 COMPOUNDS AND PHARMACEUTICAL USES THEREOF SYNEURX INTERNATIONAL (TAIWAN) CORP. (CN) 2021-10-28 WO disclosed
US-20210228727-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS CIDARA THERAPEUTICS, INC. (US) 2021-07-29 US disclosed
US-20180169641-A1 BENZO[H]QUINOLINE LIGANDS AND COMPLEXES THEREOF JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) 2018-06-21 US disclosed
US-20180148465-A1 PROCESS UNIVERSITA DEGLI STUDI DI UDINE (IT) 2018-05-31 US disclosed
US-9243238-B2 Synthetic enzymes derived from computational design UNIVERSITY OF WASHINGTON (US) 2016-01-26 US disclosed
EP-1819684-B1 SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS INTERVET INT BV (NL) 2013-08-07 EP disclosed
EP-1392280-A2 ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF Abbott GmbH & Co. KG (DE) 2004-03-03 EP disclosed
US-20030212123-A1 COX-2 selective carprofen for treating pain and inflammation in dogs PFIZER INC. 2003-11-13 US disclosed
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY 2003-05-22 US disclosed
WO-2002089749-A2 ARYLSULFONAMIDE ETHERS, AND METHODS OF USE THEREOF ABBOTT GMBH & CO.KG (DE) 2002-11-14 WO disclosed
EP-0822174-B1 Process for the preparation of a naphthylbutanone ARCHIMICA SPA (IT) 2000-05-31 EP disclosed
EP-0988034-A1 COX-2 SELECTIVE CARPROFEN FOR TREATING PAIN AND INFLAMMATION IN DOGS PFIZER INC. (US) 2000-03-29 EP disclosed
WO-1998050033-A1 COX-2 SELECTIVE CARPROFEN FOR TREATING PAIN AND INFLAMMATION IN DOGS PFIZER INC. (US) 1998-11-12 WO disclosed
US-5777170-A Process for the preparation of a naphthylbutanone ARCHIMICA SPA (IT) 1998-07-07 US disclosed
EP-0822174-A1 Process for the preparation of a naphthylbutanone Archimica S.p.A. (IT) 1998-02-04 EP disclosed
US-3966814-A PERIPHERAL VASODILATORS, ANTIHISTAMINES, SPASMOLYTICS BOEHRINGER INGELHEIM GMBH (DT) 1976-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180169641-A1 BENZO[H]QUINOLINE LIGANDS AND COMPLEXES THEREOF BRD4, NQO1, NQO2 TDP1 1608/4885ATM 3277/4885L3MBTL1 3418/4885
US-20240024497-A1 METHODS FOR THE SYNTHESIS OF PROTEIN-DRUG CONJUGATES RNGTT, RNMT, DNPEP TDP1 3431/4885ATM 4789/4885L3MBTL1 3063/4885
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof CASP1, IRAK1, STS TDP1 1116/4885ATM 2414/4885L3MBTL1 2397/4885
US-20030212123-A1 COX-2 selective carprofen for treating pain and inflammation in dogs PTGES2, PTGER2, PTGS2 TDP1 3929/4885ATM 4006/4885L3MBTL1 2096/4885
US-20210228727-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS FCGR3B, ALB, FCGR1A TDP1 4479/4885ATM 4701/4885L3MBTL1 3340/4885
US-11833213-B2 Compositions and methods for the treatment of viral infections FCGR3B, ALB, FCGR1A TDP1 4479/4885ATM 4701/4885L3MBTL1 3340/4885
US-20180148465-A1 PROCESS OSTC, AP2S1, LGALS4 TDP1 3676/4885ATM 2387/4885L3MBTL1 4827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.